ArticleMolecules (Basel, Switzerland)2019
Synthesis and AChE-Inhibitory Activity of New Benzimidazole Derivatives.
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 58 citations in OpenAlex.
- Article
- An Insight into Medicinal Chemistry and SAR Studies of Cholinesterase and BACE-1 Inhibitors for Alzheimer's Disease.CNS & neurological disorders drug targets · 2026Review
- Benzimidazole Derivatives in Alzheimer's Therapy: Exploring Multi-Target Pathways.Current protein & peptide science · 2026Review
- Innovative approaches in acetylcholinesterase inhibition: a pathway to effective Alzheimer's disease treatment.Molecular diversity · 2025Review
- Synthesis and biological evaluation of novel hydrazone derivatives for the treatment of Alzheimer's disease.RSC advances · 2025Article
- Synthesis, biological evaluation, and docking analysis of novel benzimidazole-triazole hybrids as potential anticancer agents.RSC advances · 2025Article
- Article
- Synergistic Autophagy-Related Mechanisms of Protection Against Brain Aging and AD: Cellular Pathways and Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Exploring the Benzazoles Derivatives as Pharmacophores for AChE, BACE1, and as Anti-Aβ Aggregation to Find Multitarget Compounds against Alzheimer's Disease.Molecules (Basel, Switzerland) · 2024Review
- A Critical Review on Therapeutic Potential of Benzimidazole Derivatives: A Privileged Scaffold.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
- In Vitro and In Silico Evaluations of the Antileishmanial Activities of New Benzimidazole-Triazole Derivatives.Veterinary sciences · 2023Article
- Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review.Antibiotics (Basel, Switzerland) · 2023Review
- Synthesis and Molecular Docking of New N-Acyl Hydrazones- Benzimidazole as hCA I and II Inhibitors.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2023Article
- Synthesis of novel benzothiazole derivatives and investigation of their enzyme inhibitory effects against Alzheimer's disease.RSC advances · 2022Article
- Design, Synthesis, and Evaluation of Novel 2Molecules (Basel, Switzerland) · 2022Article
- Design, Synthesis, and Structure-Activity Relationships of Thiazole Analogs as Anticholinesterase Agents for Alzheimer's Disease.Molecules (Basel, Switzerland) · 2020Article
- Synthesis and bioactivities of 1-(4-hydroxyphenyl)-2-((heteroaryl)thio)ethanones as carbonic anhydrase I, II and acetylcholinesterase inhibitors.Turkish journal of chemistry · 2020Article
- Biological Evaluation, Molecular Docking, and SAR Studies of Novel 2-(2,4-Dihydroxyphenyl)-1Biomolecules · 2019Article
- SAR-mediated Similarity Assessment of the Property Profile for New, Silicon-Based AChE/BChE Inhibitors.International journal of molecular sciences · 2019Article
- Synthesis and AChE Inhibitory Activity of Novel Thiazolylhydrazone Derivatives.Molecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), one of the main causes of aged dementia, is a progressive and degenerative neurological disorder characterized by loss of cognition and memory. Although the symptomatic treatment of AD, particularly acetylcholinesterase inhibitors (AChEIs) based on the 'cholinergic hypothesis', has been successful in clinic, at present there is no cure for this disease. In this study, we designed compounds carrying benzimidazole and triazole rings on the same chemical skeleton so as to investigate their potential acetylcholinesterase and butyrylcholinesterase activity. Furthermore, molecular modeling study was performed to determine the binding mode of the best inhibitor to the AChE. Among them, compounds
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.